Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance and Interoception in Healthy Individuals and Panic Disorder.
Key facts
- Who runs it
- Uppsala University
- Where
- Sweden2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 42 people enrolled
- Started
- 29 Oct 2024
- Ended
- 15 May 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Caffeine
- Placebo
- Record updated
- 27 February 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Panic Disorder group (PD): Primary diagnosis of Panic Disorder
- Healthy control group (HCs): No current or history of psychiatric disorders
- All participants (PD and HCs): Weekly caffeine consumption ≤ 300 mg
Who cannot take part
- Thoracic or head surgery, or any other surgery or metallic implanted devices not compatible with the safety standards for 7T MR scanner
- Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months
- Current drug or alcohol abuse/dependency
- History of severe psychiatric disorder (e.g., schizophrenia)
- Somatic or neurological conditions (e.g., hypertension and heart condition)
- Uncorrected visual or hearing impairment
- Weekly caffeine consumption ≥ 300 mg
- Other ongoing treatments that may confound the results
- Habitual nicotine use
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The current study is a placebo-controlled, double-blind, randomized controlled study using a cross-over design, including Healthy Controls (HC) and participants with Panic Disorder (PD).
Read full original descriptionShow less
The primary aim of the study is to investigate the neural correlates and behavioral effects of caffeine (versus placebo), and its impact on emotional reactivity, decision-making, and interoception, and compare the effects in individuals with PD vs HCs. Subjective anxiety and the occurrence of panic attacks will also be measured. Multimodal neuroimaging methods, such as structural and functional MRI, will be used to address the aims of the study.
Emotional reactivity, emotional decision-making and interoception will be measured with experimental tasks in a 7 Tesla (7T) magnetic resonance (MR) scanner, jointly with measures of skin conductance, heart rate, respiratory rate, and self-reported ratings of anxiety and interoception.
Emotional reactivity will be assessed using emotional and neutral faces. Emotional decision-making will be assessed with an approach-avoidance conflict task. Changes in interoception (bodily sensation, such as pulse and respiration) will be explored using a task in which participants are asked to focus on their breathing or an external stimulus. Caffeine effects on brain resting-state activity will also be assessed. All tasks will be conducted while in the 7T MR scanner.
A secondary aim of the study is to examine the impact of genetic variability in the adenosine A2A receptor (ADORA2A) genotype (e.g., rs5751876 T/T) on the effects of caffeine (vs placebo), as ADORA2A genotype has previously been associated with elevated caffeine-induced anxiety.
The 2 groups in the trial
- Panic DisorderOther group
Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
Treatment: Caffeine and Placebo
- Healthy controlsOther group
Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete session 2 with the other condition (condition not allocated to in session 1).
Treatment: Caffeine and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adenosine Receptors From Genes to Behavior: Neurobehavioral Correlates of Caffeine on Anxiety, Avoidance, Decision-Making and Interoception in Healthy Individuals and Panic Disorder.
- Record updated
- 27 February 2026